Can Amlodipine Be Taken at Night?

Amlodipine's Pharmacokinetics Favor Flexible Timing

Amlodipine belongs to the dihydropyridine calcium channel blocker class, and it has the longest half-life in that group. The drug reaches peak plasma concentration between 6 and 12 hours after ingestion, then clears slowly with a terminal half-life averaging 30 to 50 hours according to the FDA prescribing information [1]. That pharmacokinetic profile is what separates amlodipine from shorter-acting agents like nifedipine or felodipine.

Because of this extended half-life, amlodipine produces a near-flat 24-hour blood pressure reduction once steady state is reached (typically by day 7 or 8 of daily dosing). A 2004 analysis published in the American Journal of Hypertension measured ambulatory blood pressure in patients on amlodipine and found the trough-to-peak ratio exceeded 80%, confirming consistent coverage across the full dosing interval [2]. Shorter-acting calcium channel blockers often require careful timing to cover the early-morning blood pressure surge. Amlodipine does not share this limitation.

The practical result: whether a patient takes amlodipine at 7 AM or 10 PM, circulating drug levels remain therapeutic throughout the 24-hour period. This makes dosing time a matter of adherence convenience rather than pharmacologic necessity.

The TIME Trial Settled the Morning vs. Evening Question

For years, the question of antihypertensive dosing time lacked a definitive randomized answer. That changed in 2022 with the Treatment in Morning versus Evening (TIME) trial, published in The Lancet [3].

TIME enrolled 21,104 adults with hypertension across the United Kingdom and randomized them to take all of their antihypertensive medications either in the morning (6:00 AM to 10:00 AM) or in the evening (8:00 PM to midnight). The primary endpoint was a composite of vascular death, nonfatal myocardial infarction, and nonfatal stroke. After a median follow-up of 5.2 years, the evening group experienced a primary event rate of 3.4% compared to 3.7% in the morning group (HR 0.95 to 95% CI 0.83 to 1.10, P=0.53) [3].

No difference. The finding held across subgroups defined by age, sex, baseline blood pressure, and drug class, including calcium channel blockers. The TIME investigators concluded that patients should take their medications at whichever time promotes the best adherence.

This was the largest randomized trial ever conducted on antihypertensive chronotherapy, and it produced a clear null result. For amlodipine specifically, the combination of TIME's outcome data and the drug's inherently long half-life provides strong evidence that timing does not affect cardiovascular protection.

Earlier Chronotherapy Trials and Their Limitations

Before TIME, two Spanish trials generated considerable interest in bedtime dosing. The MAPEC trial (N=2,156), published in Chronobiology International in 2010, reported that patients randomized to take at least one antihypertensive at bedtime had lower ambulatory blood pressure during sleep and a 61% relative reduction in cardiovascular events over 5.6 years of follow-up [4]. The subsequent Hygia Chronotherapy Trial (N=19,084), published in the European Heart Journal in 2019, reported an even more dramatic 45% relative reduction in the composite cardiovascular endpoint with bedtime dosing [5].

These results seemed significant. They also drew immediate scrutiny.

Multiple independent analyses raised serious methodological concerns about Hygia. A 2020 commentary in the European Heart Journal noted event rates in the morning-dosing control arm that were implausibly high compared to other large hypertension trials [6]. The reported hazard ratios exceeded what statin therapy achieves for secondary prevention, a magnitude that strained biological plausibility for a simple timing change. The International Society of Hypertension issued a position statement advising clinicians not to change prescribing practice based on Hygia alone, pending independent replication [7].

TIME provided that replication. It found nothing.

The current evidence base therefore favors the interpretation that bedtime dosing of antihypertensives, including amlodipine, does not confer a meaningful cardiovascular advantage over morning dosing. Clinicians who adopted bedtime-first prescribing after Hygia can reassure patients that either timing is acceptable.

When Evening Dosing Might Still Make Sense

Although large-scale outcome data show no timing advantage, some individual clinical scenarios favor a bedtime dose of amlodipine. The key consideration is nocturnal blood pressure patterns.

Ambulatory blood pressure monitoring (ABPM) classifies patients by their nighttime dipping pattern. Normal dippers show a 10% to 20% decline in systolic pressure during sleep. Non-dippers (less than 10% decline) and reverse dippers (nighttime pressure higher than daytime) carry higher cardiovascular risk. A 2018 meta-analysis in Hypertension (N=17,312) found that elevated nighttime systolic blood pressure was a stronger predictor of cardiovascular events than daytime readings, independent of 24-hour average pressure [8].

For patients identified as non-dippers or reverse dippers on ABPM, a physician may choose bedtime amlodipine dosing to shift peak drug effect toward the overnight hours. While the 30-to-50-hour half-life blunts any sharp pharmacodynamic peak, the 6-to-12-hour time to Cmax does mean slightly higher plasma levels during the hours immediately following dosing [1].

Other practical reasons to favor evening dosing include:

• Workplace routines: patients who leave home early and forget morning pills may find bedtime dosing more reliable
• Medication bundling: if a patient already takes another drug at bedtime (a statin, for example), adding amlodipine to that same time simplifies the regimen
• Dizziness management: a small subset of patients report mild lightheadedness when amlodipine reaches peak levels; taking the dose before sleep lets them sleep through this window

These are adherence and tolerability considerations, not pharmacologic mandates. The choice should be individualized.

Side Effects and Their Relationship to Dosing Time

Peripheral edema is the most clinically relevant side effect of amlodipine. According to the FDA label, peripheral edema occurs in 1.8% of patients at 5 mg daily and 10.8% at 10 mg daily [1]. This edema results from precapillary arteriolar dilation without a matching postcapillary response, allowing fluid to accumulate in dependent tissues. It is dose-dependent and positional.

Some clinicians hypothesize that evening dosing could reduce perceived edema because peak drug effect coincides with the supine position, when gravitational fluid redistribution is minimal. No randomized trial has tested this hypothesis directly for amlodipine. A small crossover study of another dihydropyridine, cilnidipine, suggested reduced ankle edema with bedtime dosing, but the sample was only 20 patients [9]. This remains speculative for amlodipine.

Other common adverse effects include headache (7.3%), fatigue (4.5%), and dizziness (3.4%) per the prescribing information [1]. These are generally mild and tend to attenuate within the first two weeks. Patients who find dizziness bothersome during daytime activities may prefer to shift the dose to bedtime, though this is an anecdotal strategy without controlled evidence.

Gingival hyperplasia, reported in roughly 1% to 3% of long-term users per a systematic review in the Journal of Clinical Periodontology [10], is not influenced by dosing time. Neither is the rare but documented association between amlodipine and elevated hepatic transaminases.

What Guidelines Say About Timing

Major hypertension guidelines do not specify a time of day for amlodipine or other long-acting antihypertensives.

The 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults recommends thiazide diuretics, ACE inhibitors, ARBs, or calcium channel blockers as first-line agents but does not address dosing time [11]. The 2023 European Society of Hypertension (ESH) guidelines, published in the Journal of Hypertension, explicitly addressed the chronotherapy question following the TIME trial results. The ESH stated: "There is no convincing evidence that evening dosing of antihypertensive medications provides superior cardiovascular protection compared with morning dosing" [12].

The Endocrine Society's 2020 clinical practice guideline on hypertension in endocrine disorders similarly omits timing-specific recommendations, focusing instead on target blood pressure thresholds and drug selection [13].

One area where timing guidance does appear is for short-acting antihypertensives and diuretics. Diuretics are often prescribed in the morning to avoid nocturia. Short-acting calcium channel blockers like immediate-release nifedipine require twice-daily dosing timed to cover the morning surge. Amlodipine's once-daily, timing-flexible profile is precisely why it became the most prescribed calcium channel blocker worldwide.

Circadian Blood Pressure Patterns and Why They Matter

Blood pressure follows a predictable circadian rhythm in most people. It dips during sleep (the nadir typically occurring between 2 AM and 4 AM), then surges in the early morning hours between 4 AM and 10 AM. This morning surge correlates with a well-documented peak in cardiovascular events. A pooled analysis of over 60,000 patients published in Hypertension found that stroke incidence peaks between 6 AM and noon, with a relative risk 1.49 times higher than during the overnight period [14].

The rationale for morning dosing of antihypertensives has historically centered on blunting this surge. For short-acting drugs, the logic holds: if the drug is active for only 8 to 12 hours, morning dosing ensures coverage during the highest-risk window.

Amlodipine operates differently. Its extended half-life means drug levels barely fluctuate between dose intervals once steady state is achieved. A pharmacokinetic modeling study estimated that at steady state, the difference between peak and trough amlodipine plasma concentrations is only about 25%, compared to 60% or more for shorter-acting agents [2]. This narrow oscillation means the morning blood pressure surge is covered regardless of when the dose was taken.

For patients whose clinician has ordered 24-hour ambulatory monitoring and identified an abnormal nocturnal pattern, dosing time becomes a more nuanced conversation. But for the majority of hypertensive patients with normal dipping patterns, the timing of amlodipine is simply a convenience decision.

Practical Guidance for Patients

The best time to take amlodipine is the time you will take it every day. Consistency matters more than clock position.

If you currently take amlodipine in the morning and tolerate it well, there is no evidence-based reason to switch. If you consistently forget your morning dose and believe a bedtime routine would improve adherence, switching is safe and does not require a taper or washout period.

Patients switching from morning to evening dosing should take their usual morning dose, then take the next dose at bedtime the following day. This creates a roughly 36-hour gap, which is well within amlodipine's half-life window and will not produce a clinically meaningful drop in plasma levels [1]. There is no need to double up or take a half-dose to "bridge" the transition.

If you take amlodipine alongside a thiazide diuretic, separating the two may help: amlodipine at bedtime and the diuretic in the morning. This avoids nighttime trips to the bathroom while maintaining 24-hour blood pressure coverage from both agents.

The American Heart Association's 2024 advisory on medication adherence found that fixed dosing times linked to daily routines (brushing teeth, a specific meal, or a bedtime ritual) improved adherence rates by 15% to 20% compared to unstructured timing [15]. Picking a cue and linking amlodipine to it is more valuable than debating morning versus night.